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FIRST ANALYSIS OF CLINICAL SIGNIFICANT INTERACTIONS
IN HIGH-RISK CARDIOVSCULAR PATIENTS ENROLLED INTO
HOPE-TOO TRIAL IN SLOVAKIA IN THE THIRD YEAR OF TRIAL
PARTICIPATION
Foltánová T1,Thurzo M2, Lietava J2,Tumova I1, Lonn E3, Fodor JG4
1Faculty of Pharmacy, Comenius University, Bratislava, Slovakia; 22-nd
Department of Internal Medicine, Comenius University, Bratislava,
Slovakia; 3Hamilton University, Hamilton Canada; 4University of
Ottawa Heart Institute, Ottawa, Canada
OBJECTIVES: To monitor the therapy of high risk cardiovas-
cular patients enrolled into HOPE TOO trial in Slovakia and to
determine the prevalence of clinical signiﬁcant interactions in this
cohort in the third year of the investment. METHODS: Therapy
of 849 high-risk ischemic heart disease (IHD) patients (deﬁned
as age over 55yrs), symptomatic IHD [deﬁned as myocardial
infarction (MI), unstable angina pectoris (UAP)], stroke, periph-
eral vascular disease and diabetes mellitus (DM) with at least one
more risk factor (arterial hypertension or hypercholesterolemia
or smoking) was analysed during HOPE-TOO study enrollment
and during the second year visit. RESULTS: High risk cohort
aged 69.27 yrs (57–90) consisted of 79.9% pts with arterial
hypertension, of 62.5% with DM, of 45.6% pts with prior MI,
and of 17.7% pts with stroke. In third year of the trial partici-
pation average number of drugs was 6.57 (0–20) and 442
(60.47%) pts used more than 6 drugs. Clinically important inter-
actions (grade1,2) were presented in 241 (32.97%) pts. Most 
frequent interactions were with digoxin coprescribed with
furosemid—61 (8.34%) pts., digoxin-simvastatin—19pts.
(2.60%), digoxin-amilorid—16 (2.19%) pts. Average age in the
women’s group was 69.5yrs. Women took an average of 7.22
medications and the average interaction was 0.24. Average age
in the men’s group was 69.04yrs. Compared to the women, men
took only 5.96 drugs and the average interaction was 0.24.
CONCLUSION: High-risk cardiovascular patients are directly
endangered by polypragmacy and drug interactions even during
a three year follow up. Structure of their therapy must be care-
fully monitored.
CARDIOVASCULAR
CARDIOVASCULAR—Cost Studies
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THE COST-EFFECTIVENESS OF IRBESARTAN IN THE
TREATMENT OF HYPERTENSIVE TYPE 2 DIABETIC PATIENTS
WITH MICROALBUMINURIA IN CHINA
Hu S1, Chen W1,Annemans L2
1Fudan University, Shanghai, China; 2HEDM, Meise, Belgium
OBJECTIVES: To project the cumulative incidence of end-stage
renal disease (ESRD), life expectancy and costs in China of treat-
ing patients with diabetes, hypertension, and microalbuminuria
(DHM) with either standard hypertension treatment alone or
standard hypertension treatment plus irbesartan 300mg daily.
METHODS: A peer-reviewed Markov model that simulated pro-
gression from microalbuminuria to nephropathy, doubling of
serum creatinine, ESRD, and all-cause mortality in patients with
DHM was adapted to China. Three strategies were compared:
A) early use of irbesartan (i.e. start treatment in subjects with
microalbuminuria) versus B) late use of irebesartan (i.e. as from
overt nephropathy), or C) standard hypertension care (with com-
parable blood pressure control). Cumulative incidence of ESRD,
costs and life expectancy were projected for a hypothetical
cohort of 1000 subjects. Treatment-speciﬁc progression and
mortality probabilities were derived from published trials:
IRMA-2 (in microalbuminuria) and IDNT (in overt nephropa-
thy). Medical management and cost data per state were obtained
from published local sources. A ﬂexible time horizon up to 25
years and third party payer perspective were used. Future costs
and LE were discounted at 3% yearly. RESULTS: When com-
pared to standard blood pressure control, early irbesartan was
projected to reduce the cumulative incidence of ESRD from
(mean ± standard deviation) 22% to 8%, save RMB 30,348 (US
$3,667), and add 0.638 life years per treated patient. Late irbe-
sartan was dominant to control but dominated by early irbesar-
tan. The superiority of early use of irbesartan over standard care
was robust for most variables, except for the cost of dialysis and
the time horizon. Break-even occurred after 13 years. CON-
CLUSIONS: Treating DHM patients with early irbesartan was
projected to reduce the incidence of ESRD, extend life and reduce
costs. Treating patients at a later stage is still beneﬁcial, however
to a lower extent. Applying ﬂexible time horizons shows addi-
tional relevant information to decision makers.
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LONG-TERM COST-EFFECTIVENESS OF CLOPIDOGREL® IN
PATIENTS WITH ACUTE CORONARY SYNDROME WITHOUT
ST-SEGMENT ELEVATION IN GERMANY
Brüggenjürgen B1, Ehlken B2
1Alpha Care GmbH, Celle, Germany; 2MERG, Medical Economics
Research Group, Munich, Germany
OBJECTIVE: Patients with acute coronary syndrome without
ST-segment elevation receiving Clopidogrel in addition to acetyl-
salicylic acid (ASS) showed 20% risk reduction in the CURE
trial. Economic models for assessing the impact on costs exist
for several countries, however not for Germany on a long-term
basis. The objective of this model adaptation is to assess the long-
term economic impact of Clopidogrel taken in addition to ASS
in Germany. METHODS: A Markov model with six states (at
risk, ﬁrst year with stroke, following years with stroke, ﬁrst year
with new myocardial infarction (MI), following years with MI
and death) was adapted for Germany. Model outcome was life-
years saved. Cost and effects of one year treatment were calcu-
lated based on the CURE trial. Resource use for the different
health states during follow-up were based on desk research or
on expert opinion, which included costs for drugs, physician
visits, hospitalisation, rehabilitation and nursing. Risk data for
MI and stroke were based on Swedish data. The model calclu-
lates life-time costs and survival length. Costs were estimated
from the payers’l perspective within the German health care
system. Sensitivity analysis varied follow-up treatment costs at 
-50% and +100%. RESULTS: The Markov analysis resulted in
8.89 life-years saved for the placebo treatment group and 9.02
for the Clopidogrel® treatment group. The cumulated cost were
9288 and 9653 resp. The incremental cost effectiveness ratio
(ICER) was 2670€ for each life-years saved. In the sensitivity
analysis halving of follow-up cost lead to an ICER at 3666€ and
doubling to 677€. CONCLUSION: Our results are in line with
results in other Health Care systems. Adding Clopidogrel in
addition to ASS for patients with acute coronary syndrome
without ST-segment elevation generates an additional life-year
saved at a comparably low value of 2670€ in Germany.
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OBJECTIVES: To determine in Italy the incremental cost per life
year saved (ICLYS) of clopidogrel versus ASA in secondary pre-
vention of ischemic stroke (IS), myocardial infarction (MI), or
vascular death in four high risk atherothrombotic populations:
1) with prior IS or MI to index event; 2) treated for hypercho-
lesterolemia and/or with diabetes; 3) polyvascular; and 4) with
prior cardiac surgery (CABG). METHODS: The economic
analysis was performed from the Italian Health Care System per-
spective using only direct medical costs. A Markov model
designed with 7 clinical states calculated ICLYS as the cost
needed to achieve an extra life year with a two-year treatment
with clopidogrel compared to ASA, over a lifetime horizon. The
model combined clinical outcomes from the CAPRIE trial data-
base and survival data derived from the Saskatchewan database.
The costing of events, including acute care and two-year follow-
up, was evaluated using ofﬁcial data for DRGs, tariffs and/or
charges (physicians fees, examinations, lab tests). A discount rate
of 3% was applied to costs and lifetime effects. RESULTS: Per
1000 patients treated with clopidogrel the additional ischemic
events avoided and the gain in life years were: 27 events and 119
years in prior IS or MI patients; 28 events and 130 years in
hypercholesterolemic and/or diabetic patients; 24 events and 138
years in polyvascular patients; 82 events and 474 years in prior
CABG patients. The ICLYS of clopidogrel compared to ASA
were 9055€ in prior IS or MI group, 7880€ in patients treated
for hypercholesterolemia and/or diabetes, 8216€ in polyvascular
patients and 2001€ in CABG patients. Results were robust under
a wide variation of key parameters. CONCLUSION: In Italy a
two-year treatment with Clopidogrel as an alternative to ASA is
a cost-effective strategy in secondary prevention of ischemic fatal
and non-fatal events for high-risk atherothrombotic patients.
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THE COST-EFFECTIVENESS OF CLOPIDOGREL IN ACUTE
CORONARY SYNDROMES WITHOUT ST-SEGMENT
ELEVATION IN POLAND
Pietrasik A1, Niewada M1, Spiesser J2, Gabriel S3
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OBJECTIVES: The CURE study has demonstrated that treat-
ment strategy involving clopidogrel plus aspirin, comparing to
aspirin alone, signiﬁcantly reduced the risk of cardiovascular
death, myocardial infarction and stroke in patients with ACS
without ST-segment elevation. For every 1000 patients treated
with clopidogrel there were 20 less strokes, myocardial infarc-
tions or cardiovascular deaths (crude NNT = 50). The purpose
of the present study was to evaluate cost-effectiveness of clopi-
dogrel in Poland based on CURE trial efﬁcacy data. METHODS:
Data on resource use i.e. hospitalizations, medical procedures,
concomitant medications and study drug were derived from case
report form of CURE trial. Unit costs were calculated using
drugs retail prices and medical procedures tariffs contracted by
National Health Found. Cost-effectiveness was expressed as cost
per cardiovascular event avoided. The time horizon was the
mean study duration of 9 months. All costs are expressed in
EURO and EURO-PPP (1EURO = 2.08 PLN’ PPP2003).
RESULTS: Mean direct treatment cost per patient was higher in
clopidogrel than control group (2395 and 1931€; 5074€, and
4100€, PPP, respectively). The observed difference was attribut-
able mostly to a higher acquisition cost of clopidogrel. The mean
cost of initial and subsequent hospitalizations (including study
drug) was reduced for clopidogrel group by 18 and 24€, 40, and
53€-PPP, respectively. The estimated incremental cost per event
avoided amounted to 23,076€ and 48,497 EURO-PPP. CON-
CLUSIONS: Treatment with clopidogrel resulted in reduction of
initial and subsequent hospitalizations costs. The cost per event
avoided with clopidogrel in patients with ACS is consistent with
results from other countries and compares well to other treat-
ment strategies in patients with cardiovascular disease.
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OBJECTIVES: Results from the PCI-CURE trial demonstrated
that treatment strategy involving clopidogrel plus aspirin, com-
paring to aspirin alone, signiﬁcantly reduced the risk of cardio-
vascular death, myocardial infarction and stroke in patients with
acute coronary syndromes (ACS) without ST-segment elevation
undergoing percutaneous coronary interventions (PCI). The
purpose of the present study was to evaluate cost per event
avoided in the PCI subgroup of CURE trial, in Poland.
METHODS: Data on resource use, i.e. hospitalizations, medical
procedures, concomitant medications and study drug were
derived from case report form of PCI-CURE trial. Unit costs
were calculated using drugs retail prices and medical procedures
tariffs contracted by National Health Found. Cost-effectiveness
was expressed as cost per cardiovascular event avoided. The time
horizon was the mean study duration of 8 months. All costs are
expressed in EURO and EURO’PPP (1€ = 2.08 PLN’ PPP2003).
RESULTS: Mean direct treatment cost per patient was higher 
in clopidogrel than control group (2700 and 2248€, 5711, and
4759€’PPP, respectively). The observed difference was attribut-
able mostly to a higher acquisition cost of clopidogrel. The mean
cost of initial hospitalizations (including study drug) was reduced
for clopidogrel group by 26€, 57€’PPP. The estimated incremen-
tal cost per event avoided amounted to 12,858€, 27,043€’PPP.
CONCLUSIONS: Treatment with clopidogrel resulted in reduc-
tion of initial hospitalizations costs. The cost per event avoided
with clopidogrel in patients undergoing a PCI is comparable to
other interventions in this area considered as cost-effective.
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COST-EFFECTIVENESS ANALYSIS OF ALTEPLASE COMPARED
WITH STREPTOKINASE AND ABSENCE OF
THROMBOLYTICAL THERAPY FOR MYOCARDIAL
INFARCTION
Derkach E,Avxentieva M,Vorobjov PA
Moscow medical academy, Moscow, Russia
OBJECTIVE: to perform cost-effectiveness analysis of alteplase
compared with streptokinase and absence of thrombolytical
therapy for myocardial infarction (MI) in Russia. METHODS:
Data on effectiveness of treatment and resource use were
extracted from hospital medical charts randomly selected from
10 city hospitals in a retrospective study. A total of 133 patients
received alteplase, 97 patients received streptokinase and 131
patients did not receive thrombolytical therapy. Effectiveness was
assessed by death rate, presence of anginal pains, arrhythmia and
heart failure at discharge. Direct medical costs were calculated
on the basis of price-lists for medical services of an insurance
company and median prices for drugs given in a wholesale phar-
maceutical informational bulletin. Incremental cost-effectiveness
ratio (ICER) was calculated for alteplase vs streptokinase and no
thrombolytical therapy and for streptokinase vs no thrombolyt-
ical therapy. RESULTS: There was no signiﬁcant difference in
death rate between 3 groups. Patients from alteplase group sig-
niﬁcantly less often had heart failure by the end of hospital treat-
